Palbociclib vs. Ribociclib: Indian Breast Cancer Study
In a groundbreaking study emerging from India, researchers have conducted a meticulous head-to-head comparison of two prominent cyclin-dependent kinase 4/6 (CDK4/6) inhibitors—Palbociclib and Ribociclib—in managing...